Use Of Dipeptidyl peptidase‐4 Inhibitors And Prognosis Of COVID‐19 In Hospitalized Patients With Typ

By performing this secondary analysis of the CORONADO study, researchers sought to determine how routine use of dipeptidyl peptidase‐4 (DPP‐4) inhibitors is associated with COVID‐19 infection severity. Participants were 2,449 patients suffering from type 2 diabetes (T2D) admitted for COVID‐19 in 68 French centres. Prior hospitalization, 596 patients were under DPP‐4 inhibitors. The composite primary endpoint integrated tracheal intubation for mechanical ventilation and death within 7 days of admission. In users and non‐users of DPP‐4 inhibitors, similar rates of occurrence of the primary outcome were evident. In propensity analysis, no significant link between use of DPP‐4 inhibitors and the primary outcome within day 7 or day 28 was revealed by the Inverse Probability of Treatment Weighting‐adjusted models. Overall, experts inferred that DPP‐4 inhibitors are safe for diabetes management during the COVID‐19 pandemic and should not be discontinued.

​

Source